BioSpace News Archive

Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients.

NLS Pharmaceutics Ltd. announces that it will host a Virtual Key Opinion Leader Event to review top-line results from its Phase 2a clinical trial evaluating Quilience® (Mazindol ER) in the treatment of excessive daytime sleepiness (EDS) and cataplexy, the two core symptoms of narcolepsy.

The Board of Directors (“Board”) of AIM ImmunoTech Inc. today announced that the Company has filed its Definitive Proxy Statement in connection with AIM’s upcoming 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders.

Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022.

Predictive Oncology announced several key developments to further strengthen the company’s offerings for pharmaceutical and biotech customers.

Kahn-Sagol-Maccabi (KSM), and Valo Health, Inc. (“Valo”), announced today a first-of-its-kind multiyear collaboration in which Valo and Maccabi KSM Research and Innovation’s Biobank will jointly conduct research leveraging Valo’s Opal Computational Platform™ to identify preventive care and personalized medicine for patients.

McKesson Corporation (NYSE:MCK) today announced that it has signed a definitive agreement to acquire Rx Savings Solutions (RxSS), a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers, reaching more than 17 million current patients.

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company’s chief legal officer and corporate secretary, effective immediately.

Alligator Bioscience AB today announced that the US Food and Drug Administration (FDA) has issued a notification for the ALG.APV-527 investigational new drug application (IND), allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types.

Zealand Pharma A/S announced that clinical results from the two-part Phase 3 trial of dasiglucagon for the treatment of congenital hyperinsulinism in newborns and infants up to 12 months of age were presented at the 60th annual European Society for Paediatric Endocrinology meeting, held in Rome, September 15-17, 2022.